Urovant Sciences has reported positive topline data from the Phase IIa clinical trial of its investigational gene therapy product, URO-902, to treat overactive bladder (OAB) patients.

URO-902 is a new, locally injected plasmid human complementary deoxyribonucleic acid (cDNA) that encodes the maxi-K channel.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

It is being developed to treat individuals with OAB that is inadequately managed on treatment with oral or transdermal pharmacologic therapy.

The randomised, double-blind, placebo-controlled exploratory trial analysed the safety, efficacy and tolerability of single doses of URO-902 versus placebo.

URO-902 is given through direct intradetrusor injections into the bladder wall under local anaesthesia in individuals with OAB symptoms and urge urinary incontinence (UUI).

The trial enrolled 80 female subjects who were categorised into two cohorts. 

Subjects in one cohort received either 24mg URO-902 or placebo while the participants in the second cohort were given 48mg URO-902 or placebo into the bladder wall. 

Several outcome measures were analysed in the trial, including the impact on the number of urgency episodes, micturitions and quality of life indicators versus placebo at 12 weeks following dosing.

According to the findings, URO-902 was found to have a clinically meaningful and statistically significant impact on various outcome measures in OAB versus placebo from baseline to week 12.

Furthermore, it was demonstrated to be well tolerated versus placebo. 

In both treatment cohorts in the trial, urinary tract infection was reported to be the most common adverse event.

Urovant Sciences executive vice-president and chief medical officer Cornelia Haag-Molkenteller said: “URO-902 showed a clinically meaningful and statistically significant effect on a number of relevant outcome measures in OAB, including a number of micturitions, urgency episodes, and quality of life indicators compared to placebo, 12 weeks post-administration. 

“We are encouraged by these positive results and pending the completion of the study in fall 2022 and we look forward to discussing next steps for the URO-902 clinical development plan.”